



Press Release

December 14, 2018

JBIC IG Partners

Russia-Japan Investment Fund (RJIF) invests in R-Pharm, a leading Russian pharmaceutical company

The Russia-Japan Investment Fund (RJIF), advised by JBIC IG Partners, and its co-investors including the Russian Direct Investment Fund have acquired a stake in R-Pharm, a leading Russian pharmaceutical company.

Founded in 2001, R-Pharm is one of the most innovative pharmaceutical companies in Russia and employs over 3,600 highly qualified specialists. The company is involved in R&D, manufacturing, promotion and distribution of medicines used in hospital and specialty care.

R-Pharm partners with various international pharmaceutical companies including Japanese ones, and Mitsui & Co., Ltd., a leading Japanese trading and investment company, acquired 10% of the company's shares last year.

The Russia-Japan Investment Fund was established to pursue and implement attractive investment projects to promote economic, trade and investment cooperation between Japan and Russia. Priority sectors identified for cooperation include healthcare, development of smart cities and sustainable technologies, energy, cutting-edge technologies and developing industries and export in the Russian Far Eastern District, as well as other initiatives that will strengthen the trade and economic relations between the two countries.

Contact for further information:

Masayuki Ota

info@jbicig.com



JBIC IG Partners (<http://www.jbicig.com/en/>)

On June 30, 2017, JBIC IG Partners is established by Japan Bank for International Cooperation (JBIC) and Industrial Growth Platform, Inc.(IGPI) with the aim of creating long-term and sustainable value for investors and industries through development of global business opportunities and a disciplined investment approach.